Introduction Summit Therapeutics is a biopharmaceutical corporation that specializes in discovering, developing, and marketing drugs to combat infectious diseases. The company's primary focus is on conducting clinical trials for Clostridioides Difficile Infection (CDI) treatment. Its flagship product, Ridinilazole, is an oral antibiotic. Established in 2003, Summit Therapeutics is headquartered in Menlo Park, California. |
Disease Domain | Count |
---|---|
Infectious Diseases | 4 |
Endocrinology and Metabolic Disease | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Bispecific antibody | 1 |
Target |
Mechanism PD-1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date21 May 2024 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism Electron transfer flavoprotein modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date28 Feb 2025 |
Sponsor / Collaborator |
Start Date30 Jan 2025 |
Sponsor / Collaborator UNICANCER [+2] |
Start Date26 Oct 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Ivonescimab ( PD-1 x VEGF-A ) | Squamous non-small cell lung cancer More | Phase 3 |
SMT-738 ( ABCA1 ) | Carbapenem Resistant Bacterial Infection More | Preclinical |
DDS-03 ( Electron transfer flavoprotein ) | Gonorrhea More | Preclinical |
DIS-73285 ( Electron transfer flavoprotein ) | Gonorrhea More | Preclinical |
SMT-571 | Gonorrhea More | Preclinical |